Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer
Authors
Keywords
-
Journal
CURRENT OPINION IN ONCOLOGY
Volume 23, Issue -, Pages S3-S9
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2011-04-13
DOI
10.1097/01.cco.0000397417.75245.9c
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bevacizumab in Combination with Metronomic Chemotherapy in Patients with Anthracycline- and Taxane-Refractory Breast Cancer
- (2014) J.A. García-Sáenz et al. JOURNAL OF CHEMOTHERAPY
- Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy
- (2010) F.- C. Bidard et al. ANNALS OF ONCOLOGY
- Molecular basis of hypertension side effects induced by sunitinib
- (2010) Guadalupe Aparicio-Gallego et al. ANTI-CANCER DRUGS
- Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer
- (2010) Katherine H. Rak Tkaczuk CLINICAL THERAPEUTICS
- Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2010) David W. Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Third consensus on medical treatment of metastatic breast cancer
- (2009) S. Beslija et al. ANNALS OF ONCOLOGY
- Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab
- (2009) A. Calleri et al. CLINICAL CANCER RESEARCH
- 5018 Quality of life (QoL) in patients (pts) treated with bevacizumab (BV) and taxane therapy for locally recurrent (LR) or metastatic breast cancer (mBC)
- (2009) R. Greil et al. EJC SUPPLEMENTS
- Gastrosplenic Fistula From Hodgkin's Lymphoma
- (2009) Carolyn D. Seib et al. JOURNAL OF CLINICAL ONCOLOGY
- Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer
- (2009) Robert Gray et al. JOURNAL OF CLINICAL ONCOLOGY
- RiBBON 1 and RiBBON 2: Phase III Trials of Bevacizumab with Standard Chemotherapy for Metastatic Breast Cancer
- (2008) Joyce A. O'Shaughnessy et al. Clinical Breast Cancer
- Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer
- (2008) Silvia Dellapasqua et al. JOURNAL OF CLINICAL ONCOLOGY
- “Westernizing” Women's Risks? Breast Cancer in Lower-Income Countries
- (2008) Peggy Porter NEW ENGLAND JOURNAL OF MEDICINE
- Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
- (2007) J.-J. Mourad et al. ANNALS OF ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started